Goldline Pharmaceutical IPO Final Subscription Status

Final subscription data from BSE & NSE with category-wise breakdowns

🔥 Heating up
📈 GMP Today 🎟️ Allotment Status 📄 Full IPO Details Listed at BSE · Registrar: Bigshare Services Pvt. Ltd.
Listed SME
Price: ₹41 - ₹43 Lot: 3000 Min: ₹1,29,000 Period: 12 May - 14 May
Subscribed
840.57x
Total Demand
₹6,614 Cr
Applications
—
Build by Day
22.35x → 100.21x → 840.57x

Subscription (Shares)

CategoryOfferedAppliedTimes
QIB 5,40,000 9,73,17,000 180.22
NII 3,90,000 64,83,15,000 1,662.35
bNII (>10 Lakh) 2,60,000 43,22,10,000 1,662.35
sNII (2-10 Lakh) 1,30,000 21,61,05,000 1,662.35
Retail 9,00,000 79,26,12,000 880.68
TOTAL 18,30,000 1,53,82,44,000 840.57

Application Breakup

CategoryReservedApplicationsTimes
NII 43 1,08,052 2,512.84
bNII (>10 Lakh) 29 18,009 621.00
sNII (2-10 Lakh) 14 36,018 2,572.71
Retail 300 2,64,204 880.68
TOTAL 386 4,26,283 1,104.36

Subscription (Crores)

CategoryOfferedDemandTimes
QIB 2.32 418.46 180.22
NII 1.68 2,787.75 1,662.35
bNII (>10 Lakh) 1.12 1,858.50 1,662.35
sNII (2-10 Lakh) 0.56 929.25 1,662.35
Retail 3.87 3,408.23 880.68
TOTAL 7.87 6,614.45 840.57

Day-wise Subscription

End-of-day subscription.

Each panel has its own scale.
Day QIB NII bNII sNII Retail Total
Day 1 12 May 1.31x 24.46x 24.46x 24.46x 34.07x 22.35x
Day 2 13 May 1.31x 146.48x 146.48x 146.48x 139.51x 100.21x
Day 3 14 May 180.22x 1662.35x 1662.35x 1662.35x 880.68x 840.57x

Estimated Allotment Chance

Retail 0.13% (880.68x subscribed)
Low chance
S-HNI (2-10L) 0.06% (1,662.35x subscribed)
Low chance
B-HNI (>10L) 0.24% (1,662.35x subscribed)
Low chance
about 1 in 1,000 retail applicants are likely to get allotment.
Estimate from subscription data; the registrar's draw decides.

How Goldline Pharmaceutical’s demand compares with recent SME IPOs

Final multiples against the 192 SME IPOs listed in the last 12 months.

CategoryGoldline PharmaceuticalSME medianHigher than
Overall 841x 3.98x 100% of 192
QIB 180x 14.69x 91% of 163
NII (HNI) 1662x 5.32x 100% of 192
Retail 881x 3.5x 100% of 192

Of the 44 recent SME IPOs that finished 100x or more subscribed, 91% opened above the issue price, with a median listing-day move of +42.9%. Goldline Pharmaceutical itself listed at +39%.

Source: BSE and NSE. Not investment advice.

Goldline Pharmaceutical IPO Subscription — Detailed Analysis

Where Goldline Pharmaceutical Subscription Finished

Goldline Pharmaceutical IPO was subscribed 840.57 times overall by the close of bidding — a heavily oversubscribed level that signals strong investor demand.

Goldline Pharmaceutical IPO Subscription — FAQs

Goldline Pharmaceutical IPO was subscribed 840.57 times overall by the close of bidding.

Goldline Pharmaceutical IPO was open for subscription from May 12, 2026 to May 14, 2026.

The price band for Goldline Pharmaceutical IPO is ₹41 - ₹43 per share.

See also: reading the subscription table · allotment chances · allotment process

GMPUpdate